Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.37 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568540 | 1.00 | HTR6 (0.37) | HTR6CYP24A1KDM4EUBE2NRAPGEF4 | |
| SCHEMBL6568535 | 1.00 | HTR6 (0.37) | HTR6CYP24A1KDM4EUBE2NRAPGEF4 | |
| SCHEMBL6757596 | 1.00 | HTR6 (0.37) | HTR6CYP24A1KDM4EUBE2NRAPGEF4 | |
| SCHEMBL6757600 | 1.00 | HTR6 (0.37) | HTR6CYP24A1KDM4EUBE2NRAPGEF4 | |
| SCHEMBL6570213 | 0.79 | SMN1; SMN2 (0.33) | CYP24A1MEN1KMT2A | |
| SCHEMBL6570206 | 0.79 | SMN1; SMN2 (0.33) | CYP24A1MEN1KMT2A | |
| SCHEMBL4622561 | 0.74 | DHODH (0.34) | — | |
| SCHEMBL4622563 | 0.74 | DHODH (0.34) | — | |
| SCHEMBL4622571 | 0.74 | DHODH (0.34) | — | |
| SCHEMBL4622568 | 0.74 | DHODH (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716998-B2 | SUCH AS (2R)-3,4-DIHYDRO-2H-CHROMEN-2-YL-METHYL-4-METHYL-BENZENESULFONATE; METATHESIS RING CLOSING POLYMERIZATION | WYETH | 2004-04-06 | — | — | US | disclosed |
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | WYETH (US) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | CDYL, CDY1; CDY1B, CDYL2 | HTR6 744/4885CYP24A1 925/4885KDM4E 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.